Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
23 Apr 2018
Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.

Improved heart function, metabolic parameters with growth hormone replacement therapy

Roshini Claire Anthony
20 Aug 2018

Growth hormone (GH) replacement therapy increased left ventricular (LV) mass and improved metabolic parameters in prepubertal children with growth hormone deficiency (GHD), according to a study from Spain.

The prospective, observational study cohort comprised 81 prepubertal children (age 7–10 years; Tanner stage I), 40 of whom had GHD (24 females; growth hormone peak 7.3 ng/mL), who were compared with 41 healthy children (23 females; control group). Children with GHD were given GH replacement therapy at a dose of 0.030 mg/kg/day for 6 months. All patients had blood drawn and underwent echocardiography tests at study onset with a second round of tests at 6 months in children with GHD.

At baseline, children with GHD had smaller LV mass index than children in the control group (58.73 vs 62.77 g/m2), with size significantly increasing to 68.60 g/m2 following 6 months of GH replacement therapy to a comparable size between groups (p=0.143). [Front Pediatr 2018;6:174]

At baseline, children with GHD had smaller systolic and diastolic LV diameter compared with the control group (23.62 vs 25.93 mm and 37.17 vs 39.49 mm, respectively). GH replacement therapy significantly improved diastolic LV size (to 38.41 mm; p=0.007) to a level comparable with that of the control group but had no impact on systolic LV size (to 23.63 mm; p=0.976).

Brain natriuretic peptide (BNP) levels were comparable between children with GHD and control group at baseline (20.58 vs 17.54 pg/mL; p=0.231) and following GH replacement therapy (18.85 vs 17.54 pg/mL; p=0.874). Ejection fraction (67.06 percent vs 64.30 percent), E/A* relation (1.89 vs 1.93), E/E’** relation (6.54 vs 6.96), and isovolumic relaxation time (IVRT; 79.51 vs 87.66 mseg) were also comparable between children with GHD and controls at baseline, though following GH replacement therapy, ejection fraction and IVRT levels decreased (to 66.83 and 77.08 mseg, respectively; p=0.040 and 0.010 vs controls, respectively).

The lack of change in BNP levels following GH replacement suggests that ventricular dysfunction may not be present in prepubertal children with GHD, said the researchers.

Six months after GH replacement therapy, children with GHD experienced increases in glucose levels (from 4.72 to 4.94 mmol/L; p=0.011), HDL-cholesterol (from 54.38 to 59.18 mg/dL; p=0.035), insulin (from 7.33 to 8.25 μU/mL; p<0.001), HOMA-IR*** (from 1.53 to 1.80; p<0.001), QUICKI# (from 0.36 to 0.63; p<0.001), IGFBP3## (from 2.44 to 2.74 μg/mL; p=0.010), and IGF1### (from 185.2 to 297.3 ng/mL; p<0.001) as well as a decrease in LDL-cholesterol (from 109.1 to 99.82 mg/dL; p=0.006).

“[C]omparing the GHD children after 6 months of replacement therapy to the control group, all parameters remained significantly elevated except LDL-cholesterol, approaching baseline values; however, values were always within the normal range for age,” said the researchers.

“Adult patients with established GHD have an increased risk of cardiovascular disease and early mortality,” said the researchers. [Lancet 2001;357:425-431] “Replacement therapy with GH has beneficial effects on [several] cardiovascular risk factors, improves ventricular function, and decreases BNP, thus suggesting that GH may be effective in reducing mortality from cardiovascular disease,” they said. [Exp Clin Endocrinol Diabetes 2010;118:172-176; Horm Metab Res 2006;38:656-661]

“[A]lterations in lipid metabolism associated with GHD are present in children with this deficiency from very early ages, and replacement therapy significantly improves their lipid parameters. [H]eart size and LV mass [also] increased, with no negative effects on diastolic function,” they added.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
23 Apr 2018
Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.